Yeah. By we, I meant us, not the breast surgeons.
When I first became aware of the convos regarding B-51, I thought, just ignore the subgroup analysis...it's usually just rando (20 subgroups and chance of a type 1 error in one group is high) and ignoring usually the best thing to do.
However, we have to consider the literature outside of the trial. We now have a second trial indicating a detriment with XRT in triple negative breast cancer., where all other subgroups are pretty neutral or slightly favor the intervention.
We have a somewhat plausible mechanism? TNBC the most immunogenic of the bCa subtypes. (Also, more likely to have a true pCR to chemo relative to HR+ disease).
The data from Supremo is appropriately interpreted as demonstrating equivalence of survival outcomes. However, I would rather be on the non-XRT survival curve myself, and I believe this separation is almost completely driven by TNBC outcomes.